HIV-1 and HIV-2 are transmitted predominantly by sexual contact which involves exposure to mucosal surfaces. Previous HIV vaccine studies have focused on immunization and challenge by parenteral (IV or IM) routes using cell-free virus. This proposal will develop vaginal immunization and challenge with cell-associated virus using the SIV - rhesus macaque model of HIV infection. This model is most appropriate because the genital challenge technique is well defined, research animals are readily available and the studies can be performed economically. In this proposal we aim: 1) to identify the initial target cells in the vaginal mucosa after exposure to cell-associated virus and to determine the mechanism of virus spread to regional and systemic lymphoid tissue, and 2) to determine whether perivaginal immunization with replicating or nonreplicating SIV can generate immune responses which will protect against infection or will alter the dissemination of cell-associated SIV administered vaginally. In addition, we will determine if the immune responses which protect against vaginal challenge will also protect against SIV-infected cells inoculated intravenously. The early events of SIV infection in the genital tract leading to systemic infection will be studied, including the induction of humoral and cellular immune responses. Perivaginal immunization of female rhesus macaques with SIV immunogens will aim to stimulate local immune responses that stop the infectious process in its early stages and prevent persistent infection. Then the efficacy of vaginal immunization against IV challenge will be determined. The results of these experiments will define parameters of host immunity that are necessary for preventing the sexual transmission of HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI031383-04
Application #
2066343
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1991-09-30
Project End
1996-07-31
Budget Start
1994-08-01
Budget End
1996-07-31
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of California Davis
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Van Rompay, K K; Berardi, C J; Dillard-Telm, S et al. (1998) Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 177:1247-59
Van Rompay, K K; Otsyula, M G; Tarara, R P et al. (1996) Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J Infect Dis 173:1327-35
Otsyula, M G; Miller, C J; Marthas, M L et al. (1996) Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr Res 39:630-5
Otsyula, M G; Miller, C J; Tarantal, A F et al. (1996) Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251. Virology 222:275-8
Marthas, M L; van Rompay, K K; Otsyula, M et al. (1995) Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 69:4198-205
Lohman, B L; McChesney, M B; Miller, C J et al. (1994) Mucosal immunization with a live, virulence-attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques. J Med Primatol 23:95-101
Miller, C J; Marthas, M; Torten, J et al. (1994) Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J Virol 68:6391-400
Marthas, M L; Ramos, R A; Lohman, B L et al. (1993) Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac. J Virol 67:6047-55